Stoke Therapeutics (STOK) Revenue & Revenue Breakdown
Stoke Therapeutics Revenue Highlights
Latest Revenue (Y)
$8.78M
Latest Revenue (Q)
$4.22M
Stoke Therapeutics Revenue by Period
Stoke Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.78M | -29.22% |
| 2022-12-31 | $12.40M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Stoke Therapeutics generated $8.78M in revenue during NA 2023, up -29.22% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Stoke Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.22M | 50.46% |
| 2023-12-31 | $2.80M | -15.30% |
| 2023-09-30 | $3.31M | -233.33% |
| 2023-06-30 | $-2.48M | -148.16% |
| 2023-03-31 | $5.15M | 57.60% |
| 2022-12-31 | $3.27M | 12.53% |
| 2022-09-30 | $2.90M | -10.09% |
| 2022-06-30 | $3.23M | 7.70% |
| 2022-03-31 | $3.00M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Stoke Therapeutics generated $4.22M in revenue during Q1 2024, up 50.46% compared to the previous quarter, and up 128.97% compared to the same period a year ago.
Stoke Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $76.50M |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| RLAY | Relay Therapeutics | $25.55M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| PASG | Passage Bio | - | - |
STOK Revenue FAQ
What is Stoke Therapeutics’s yearly revenue?
Stoke Therapeutics's yearly revenue for 2023 was $8.78M, representing a decrease of -29.22% compared to 2022. The company's yearly revenue for 2022 was $12.4M, representing an increase of 100.00% compared to 2021. STOK's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Stoke Therapeutics’s quarterly revenue?
Stoke Therapeutics's quarterly revenue for Q1 2024 was $4.22M, a 50.46% increase from the previous quarter (Q4 2023), and a -18.17% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.8M, a -15.30% decrease from the previous quarter (Q3 2023), and a -14.29% decrease year-over-year (Q4 2022). STOK's quarterly revenue for Q3 2023 was $3.31M, a -233.33% decrease from the previous quarter (Q2 2023), and a 13.87% increase year-over-year (Q3 2022).
What is Stoke Therapeutics’s revenue growth rate?
Stoke Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.